Keyphrases
Bromodomain and Extra-terminal Domain
100%
Epigenetic Regulation
100%
Graft-versus-host Disease (GvHD)
95%
Bromodomain
90%
Janus Kinase 1 (JAK1)
45%
T Cell Subsets
30%
T Cells
30%
T Cell Proliferation
25%
Treg
20%
Interferon-γ
20%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
20%
Inflammatory Cytokines
20%
T Helper 17 (Th17)
20%
Costimulatory Molecules
20%
Tolerability
20%
Steroid-refractory
15%
Clinical Trials
15%
Inflammation
15%
Disease Survival
10%
PLX51107
10%
BOAST
10%
Non-benzodiazepine
10%
Non-relapse Mortality
10%
Long-term Research
10%
Ruxolitinib
10%
Benzodiazepines
10%
Strong Reduction
10%
Treatment Indication
10%
Corticosteroid Therapy
10%
Cell Viability
10%
Effector T Cells
10%
Treatment Duration
10%
Clinical Analysis
10%
Inflammatory Genes
10%
Disease Treatment
10%
Interleukin-2
10%
Disease Prevention
10%
Disease Pathogenesis
10%
Synergistic Effect
10%
T Cell Activation
10%
Interleukin-17 (IL-17)
10%
Treatment Response
10%
JAK-STAT
10%
Effective Strategies
10%
Donor T Cell
10%
Host Tissues
10%
Patient Outcomes
10%
Direct Therapy
10%
Translational Approach
10%
Clinical Approach
10%
Response to Therapy
10%
T-cell Alloreactivity
10%
Interleukin-6
10%
Cell Cycle Regulators
5%
Immune Reconstitution
5%
Improved Pharmacokinetics
5%
Cell Proliferation
5%
Synergistic Mechanism
5%
Steroid-refractory Acute Graft-versus-host Disease
5%
Pathogenic T Cells
5%
Innovative Approach
5%
Inflammatory Mediators
5%
T Cell Response
5%
FDA-approved Drugs
5%
Inflammatory Cells
5%
CD40 Ligand (CD40L)
5%
T-cell Mediated
5%
Cytokine Secretion
5%
Combination Therapy
5%
Medicine and Dentistry
Graft Versus Host Reaction
100%
T Cell
50%
Acute Graft Versus Host Disease
50%
T Cell Subset
27%
T Cell Proliferation
23%
Allogeneic Stem Cell Transplantation
18%
Inflammatory Cytokine
18%
Clinical Trial
14%
Combination Therapy
14%
Ruxolitinib
9%
Major Gene
9%
Treatment Indication
9%
Alloimmunity
9%
Nonbenzodiazepine
9%
Treatment Duration
9%
Cell Viability
9%
Prophylaxis
9%
Corticosteroid Therapy
9%
Interleukin 17
9%
Co-Stimulatory Molecule
9%
Tumor Necrosis Factor
9%
Treatment Response
9%
In Vitro
9%
Cell Function
9%
Interleukin 2
9%
Interleukin 6
9%
Non-Relapse Mortality
9%
Benzodiazepine
9%
Cytokine Release
5%
CD40 Ligand
5%
Immune Reconstitution
5%
Inflammatory Cell
5%
Pharmacokinetics
5%
Cell Cycle
5%
Inflammatory Mediator
5%
T-Cell Response
5%
Immunology and Microbiology
Graft-Versus-Host Disease
100%
T Cell
55%
Acute Graft Versus Host Disease
50%
T Cell Subset
27%
T Cell Proliferation
23%
Regulatory T Cell
18%
Allogeneic Stem Cell Transplantation
18%
Major Gene
9%
Co-Stimulatory Molecule
9%
Cell Function
9%
Tumor Necrosis Factor
9%
Mediator
9%
Cell Viability
9%
Alloimmunity
9%
Proinflammatory Cytokine
9%
Host Tissue
9%
Inflammatory Cytokine
9%
Interleukin 6
9%
Interleukin 2
9%
Interleukin 17
9%
Immune Reconstitution
5%
Cytokine Release
5%
CD40 Ligand
5%
Pharmacokinetics
5%
Cell Cycle
5%